Wockhardt Files EMA Application for Novel Antibiotic WCK 5222
ECONOMY & POLICY

Wockhardt Files EMA Application for Novel Antibiotic WCK 5222

Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222, marking a significant milestone in the company’s global regulatory journey. The application was submitted on January 5, 2026, positioning the drug for scientific evaluation across 27 European Union member states and three European Economic Area countries—Norway, Iceland and Liechtenstein—covering a total of 30 nations.

The EMA, which is responsible for the centralised assessment of new medicines in Europe, had earlier informed Wockhardt that WCK 5222 qualifies for the Accelerated Assessment pathway. This provision enables a shortened review timeline for therapies that address serious unmet medical needs, underlining the clinical importance of the antibiotic in combating resistant infections.

WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), developed to treat severe Gram-negative bacterial infections that are resistant to existing therapies. The product is already under fast-track review by the US Food and Drug Administration, reflecting growing global regulatory recognition of its potential clinical value.

Based on the clinical and regulatory data submitted, Wockhardt anticipates approval of WCK 5222 for the treatment of multidrug-resistant Gram-negative infections across all countries under the EMA’s jurisdiction. The priority status accorded to the application highlights the urgent global need for effective treatment options for patients suffering from life-threatening infections caused by antimicrobial resistance.

Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reinforcing India’s growing capabilities in advanced pharmaceutical research and innovation.

Wockhardt has filed a Marketing Authorisation Application (MAA) with the European Medicines Agency (EMA) for its novel antibiotic WCK 5222, marking a significant milestone in the company’s global regulatory journey. The application was submitted on January 5, 2026, positioning the drug for scientific evaluation across 27 European Union member states and three European Economic Area countries—Norway, Iceland and Liechtenstein—covering a total of 30 nations.The EMA, which is responsible for the centralised assessment of new medicines in Europe, had earlier informed Wockhardt that WCK 5222 qualifies for the Accelerated Assessment pathway. This provision enables a shortened review timeline for therapies that address serious unmet medical needs, underlining the clinical importance of the antibiotic in combating resistant infections.WCK 5222 is a fixed-dose combination of Zidebactam (1 g) and Cefepime (2 g), developed to treat severe Gram-negative bacterial infections that are resistant to existing therapies. The product is already under fast-track review by the US Food and Drug Administration, reflecting growing global regulatory recognition of its potential clinical value.Based on the clinical and regulatory data submitted, Wockhardt anticipates approval of WCK 5222 for the treatment of multidrug-resistant Gram-negative infections across all countries under the EMA’s jurisdiction. The priority status accorded to the application highlights the urgent global need for effective treatment options for patients suffering from life-threatening infections caused by antimicrobial resistance.Notably, WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation, reinforcing India’s growing capabilities in advanced pharmaceutical research and innovation.

Related Stories

Gold Stories

Next Story
Resources

Schindler named among Forbes’ World’s Best Employers 2026

Schindler has been named among Forbes’ World’s Best Employers 2026, a global ranking recognising companies for their workplace environments.Compiled by Forbes in partnership with Statista, the ranking is based on independent employee feedback, including whether employees would recommend their organisation to friends and family.The company said the recognition reflected its focus on creating a workplace where employees can develop their expertise and build careers. ..

Next Story
Infrastructure Urban

India needs an export-execution mindset: Vishesh Jain

Interview with Vishesh Jain, Founder & CEO, EximpleWhat gaps in India’s global trade ecosystem led you to build Eximple, and what problem did you see businesses struggling with most?Eximple came out of a problem that all three founders had seen from different choke points in the trade ecosystem. India has millions of MSMEs and manufacturers, and many of them can make products that are genuinely competitive on quality. Yet only a small fraction is able to build meaningful international businesses. In our experience, the gap is usually not manufacturing capability; it is the ability to exe..

Next Story
Building Material

Nuvoco reports 13.5% revenue growth in Q2 FY27

Nuvoco Vistas Corp. Ltd. reported consolidated revenue of Rs 27.9 billion for Q2 FY27, up 13.5% year on year. Cement sales volume rose 9% to 4.7 million tonnes (MMT), while EBITDA increased 11% to Rs 4.11 billion.The company said it began its cement operations in 2014 with a 2.3 MMT per annum (MMTPA) operation at Nimbol. It now aims to reach 35 MMTPA of cement capacity by FY28, nearly 15 times its initial capacity. Its portfolio spans cement, ready-mix concrete and modern building materials.On sustainability and cost efficiency, Nuvoco partnered with CleanMax for a 46.4 MW wind-solar hybrid re..

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

SPECIAL OFFER
QR Code